Drug Database
Back to search

Switzerland· 66520007

Olmesartan Amlo Spirig HC 20mg/5mg, Filmtabletten

A olmesartan medoxomil und amlodipin product containing olmesartanum medoxomilum, amlodipinum, registered in Switzerland by Spirig HealthCare AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 8 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC C09DB02

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedOlmesartan Amlo Spirig HC 20mg/5mg, F…ATCC09DB02REGISTER NO.66520007PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about olmesartanum medoxomilum, amlodipinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Olmesartan medoxomil und amlodipin is registered in 8 of 19 countries.

Countries holding a registration under ATC C09DB02 (olmesartan medoxomil und amlodipin), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 6 of them publish a price we can compare per daily dose
Search olmesartan medoxomil und amlodipin products by name

Olmesartan medoxomil und amlodipin · ATC C09DB02

8 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Finlandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
olmesartanum medoxomilum, amlodipinum
Manufacturer
Spirig HealthCare AG
Country
Switzerland (CH)
ATC code
C09DB02
ATC class
Olmesartan medoxomil und Amlodipin
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680665200071
    30 Stk
    CHF 30.55

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

81 interactions on record for olmesartan medoxomil und amlodipin.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check olmesartan medoxomil und amlodipin against other medicinesHow interaction checks work

Olmesartan medoxomil und amlodipin · interactions on record

81 records

81 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Olmesartan medoxomil und amlodipin in 5 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All olmesartan medoxomil und amlodipin products

Authorised across Europe · EMA

The same active substance is authorised in 8 EEA countries. Names it is sold under:

  • Belgium · Olmesartan/Amlodipine Eg
  • Bulgaria · Олмезид Am
  • Germany · Olmesartan/Amlodipin Al
  • Spain · Olmesartán/Amlodipino Stada
  • Ireland · Olmesartan/Amlodipine Clonmel
  • Italy · Olmesartan E Amlodipina Eg
  • Luxembourg · Olmesartan/Amlodipine Eg
  • Netherlands · Olmesartanmedoxomil/Amlodipine Stada

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/7e40db56-8d59-4377-8d9f-b49cea824131
GET /v1/drugs/7e40db56-8d59-4377-8d9f-b49cea824131?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "olmesartani medoxomilum 20 mg + amlodipinum 5 mg",
  "valid_from": "2021-10-01",
  "limitations": "[{\"description\":\"Die gleichzeitige Therapie mit OLMESARTAN AMLO SPIRIG HC und einem Calciumantagonisten des I.T. 02.06. und/oder einem Angiotensin-II-Antagonisten und/oder einem ACE-Hemmer wird von der obligatorischen Krankenpflegeversicherung nicht vergütet.\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-10-01\"}]",
  "galenic_form": "Filmtabl 20/5mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2018-08-01",
  "self_retention_pct": 10
}
API referenceMCP serverPlans

See everything about olmesartan medoxomil und amlodipin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console